RE HGSI, I read over the transcript and have to say I think the deal was a lot better than just OK. Considering this is a drug delivery program, modestly better dosing, not a novel breathrough like drug, $93M upfront (triggered this year), $500M in total milestones, cost split, profit split, probably decent 15-20% royalties ex-US and taken on by nvs, for a drug delivery program into a competitive field is about as good as it gets imo. nvs commitment to hcv is intense. Can't wait to see how they angle into the protease field.
Market Data 
Markets 
AI
